Ridinilazole,308362-25-6

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ridinilazole

CAS No. : 308362-25-6

MCE 国际站：Ridinilazole

产品活性：Ridinilazole 是一种新型的抗菌剂，作用于 C. difficile，MIC 范围为 0.06-0.25 µg/mL (MIC₉₀=8 µg/mL)。

研究领域：Anti-infection

作用靶点：Bacterial

In Vitro: Ridinilazole is a novel antibacterial that does not appear to act through the classical pathways associated with antibiotics, such as inhibition of cell wall, protein, lipid, RNA or DNA synthesis. Ridinilazole may impair cell division. Ridinilazole is bactericidal against C. difficile and exhibits a prolonged post-antibiotic effect. In susceptibility testing of 82 clinical isolates of C. difficile (including ribotype 027), Ridinilazole displays potent growth inhibition and has lower MICs [MIC range, 0.06-0.25 µg/mL; MIC for 90% of the organisms (MIC90), 0.125 µg/mL] than Metronidazole (MIC range, 0.125-8 µg/mL; MIC₉₀, 8 µg/mL) or Vancomycin (MIC range, 0.5-4 µg/mL; MIC₉₀, 2 µg/mL). Similarly, Ridinilazole is found to be more potent than Metronidazole or Vancomycin at inhibiting the growth of 50 ribotype-defined C. difficile strains. The activity of Ridinilazole against specific C. difficile ribotypes (including ribotypes 001, 002, 005, 014, 027, 054 and 106) is similar, with an MIC range of 0.06–0.5 µg/mL and an MIC₉₀ of 0.125 µg/mL. In addition, Ridinilazole is more active against 11 ribotype 027 strains than either Metronidazole or Vancomycin.

In Vivo: In a hamster model of CDI with a once-daily dosing regimen, Ridinilazole displays greater efficacy than Vancomycin both against non-epidemic and epidemic strains of C. difficile. Similar to the twice-daily dosing study, plasma levels of Ridinilazole are below the level of detection, whereas caecal Ridinilazole concentrations are well above the MIC, thus demonstrating the non-absorbable nature of Ridinilazole and minimal systemic exposure.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Antibacterial Compound Library  |  Anti-COVID-19 Compound Library  |  Children’s Drug Library  |  Rapamycin  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Dexamethasone  |  Puromycin dihydrochloride  |  Dimethyl sulfoxide  |  Staurosporine  |  Actinomycin D  |  G-418 disulfate  |  Etoposide  |  5-Azacytidine  |  Nigericin sodium salt  |  Brefeldin A  |  Estradiol  |  CCCP  |  Ionomycin  |  Resveratrol  |  Hygromycin B  |  Tunicamycin  |  Mitomycin C  |  Everolimus  |  Doxycycline hyclate  |  Tacrolimus  |  Methotrexate  |  Neomycin sulfate  |  Acetaminophen  |  Streptozotocin  |  Anisomycin  |  Cholesterol

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds